Hospital
Valley Children's Hospital
Valley Children's Hospital was paid $107.11M by Medicaid between Jan 2018 and Dec 2024, across 514 billing codes. Its largest line is 0360, — 11% of everything it billed.
33Billing provider infoVALLEY CHILDREN'S HOSPITAL
MADERA, CA 93636
MADERA, CA 93636
33aNPI1700949336assigned 12/18/2006
33bProvider typeChildren's Hospital
28Total paid$107.11M
24GClaims2,812,427
24DCodes billed514
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Children's Hospital providers in California
Rank by total paid#1 of 17
Median peer was paid$1.44M
This provider vs. median74×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 448,811 | $18.51M | |
| 2019 | 439,854 | $16.14M | |
| 2020 | 309,123 | $11.11M | |
| 2021 | 397,722 | $14.44M | |
| 2022 | 416,370 | $15.99M | |
| 2023 | 428,794 | $16.73M | |
| 2024incomplete | 371,753 | $14.19M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0360 | 11% | 18,412 | 15,778 | $11.57M | |
| 0450 | Emergency room services | 9.7% | 285,149 | 265,979 | $10.39M |
| Z7500 | 4.9% | 153,745 | 146,634 | $5.21M | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 4.4% | 80,185 | 75,038 | $4.76M |
| 0710 | 3.6% | 17,231 | 16,491 | $3.81M | |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.4% | 24,974 | 21,009 | $3.66M |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 2.9% | 2,967 | 2,865 | $3.10M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.4% | 30,820 | 29,089 | $2.60M |
| 70551 | Magnetic resonance imaging, brain; without contrast material | 2.2% | 4,202 | 4,100 | $2.32M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.7% | 31,372 | 29,915 | $1.81M |
| V5298 | Hearing aid, not otherwise classified | 1.7% | 1,435 | 1,435 | $1.77M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.6% | 43,330 | 42,044 | $1.74M |
502 more codes
| Z7506 | 1.5% | 13,062 | $1.58M | |
| 93325 | 1.5% | 14,888 | $1.56M | |
| 0510 | 1.4% | 20,328 | $1.52M | |
| 99285 | Emergency room visit (most serious) | 1.4% | 3,021 | $1.51M |
| 99283 | Emergency room visit (moderate) | 1.4% | 2,425 | $1.45M |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 1.3% | 3,478 | $1.44M |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 1.2% | 2,641 | $1.29M |
| 95782 | 1.1% | 1,034 | $1.14M | |
| 99215 | Doctor's office visit, returning patient (complex) | 1.0% | 6,961 | $1.09M |
| 76770 | <1% | 12,395 | $1.06M | |
| 0760 | <1% | 121,586 | $1.00M | |
| 80053 | Comprehensive metabolic panel | <1% | 92,690 | $902K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 11,530 | $866K |
| Z4300 | <1% | 8,396 | $865K | |
| Z7502 | <1% | 23,176 | $849K | |
| J0586 | Injection, abobotulinumtoxina, 5 units | <1% | 1,790 | $849K |
| 92567 | <1% | 12,036 | $767K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 87,153 | $749K |
| S0302 | Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) | <1% | 7,038 | $723K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 343 | $717K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 9,273 | $687K |
| 92557 | <1% | 5,054 | $675K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 3,347 | $620K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 16,067 | $619K |
| 0761 | <1% | 38,430 | $566K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 2,005 | $555K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,259 | $548K |
| Z4304 | <1% | 7,052 | $545K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 894 | $534K |
| 93304 | <1% | 7,207 | $509K | |
| Q3014 | Telehealth originating site facility fee | <1% | 16,133 | $507K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,318 | $499K |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | <1% | 222 | $478K |
| Z4301 | <1% | 16,986 | $435K | |
| Z7610 | <1% | 22,779 | $425K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 13,984 | $419K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 4,201 | $403K |
| L8699 | Prosthetic implant, not otherwise specified | <1% | 697 | $403K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 29,896 | $398K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 6,224 | $391K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 15,398 | $389K |
| 93975 | <1% | 5,270 | $389K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 8,949 | $373K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 3,925 | $369K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 23,146 | $367K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 25,587 | $365K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 18,592 | $356K |
| Z5822 | <1% | 6,058 | $353K | |
| Z4307 | <1% | 14,303 | $347K | |
| 96112 | <1% | 2,144 | $322K | |
| Z4308 | <1% | 12,854 | $309K | |
| T1014 | Telehealth transmission, per minute, professional services bill separately | <1% | 19,020 | $286K |
| 97799 | <1% | 8,803 | $278K | |
| 93321 | <1% | 7,849 | $274K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,219 | $244K |
| 92552 | <1% | 3,991 | $242K | |
| 95819 | <1% | 2,385 | $242K | |
| 73070 | <1% | 6,944 | $241K | |
| 82728 | <1% | 8,137 | $239K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 7,442 | $234K |
| 73100 | <1% | 6,900 | $230K | |
| 81001 | <1% | 66,499 | $229K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 5,053 | $227K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 9,408 | $227K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 11,333 | $226K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 5,448 | $224K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 3,804 | $217K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 1,894 | $209K |
| 86140 | <1% | 32,535 | $206K | |
| 87088 | <1% | 35,425 | $202K | |
| 73090 | <1% | 8,206 | $196K | |
| 92523 | <1% | 1,837 | $193K | |
| 77077 | <1% | 3,342 | $192K | |
| 94010 | <1% | 5,930 | $187K | |
| T1024 | Evaluation and treatment by an integrated, specialty team contracted to provide coordinated care to multiple or severely handicapped children, per encounter | <1% | 4,314 | $182K |
| 72141 | <1% | 281 | $181K | |
| 0700 | <1% | 9,077 | $180K | |
| 97750 | <1% | 4,644 | $178K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 2,395 | $172K |
| 92700 | <1% | 2,738 | $165K | |
| 94060 | <1% | 3,316 | $164K | |
| Z4311 | <1% | 13,571 | $164K | |
| J3490 | Unclassified drugs | <1% | 81,047 | $163K |
| 97802 | <1% | 3,107 | $162K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,306 | $160K |
| 84439 | <1% | 11,223 | $154K | |
| 74018 | <1% | 9,491 | $148K | |
| 92587 | <1% | 3,067 | $143K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,625 | $141K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 407 | $133K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 6,729 | $132K |
| Z4312 | <1% | 10,772 | $130K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,807 | $128K |
| 0160 | <1% | 2,108 | $126K | |
| 92558 | <1% | 593 | $124K | |
| 76536 | <1% | 2,321 | $122K | |
| 72082 | <1% | 2,638 | $121K | |
| 73630 | <1% | 6,333 | $120K | |
| 73610 | <1% | 6,821 | $116K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 2,695 | $115K |
| 73590 | <1% | 4,987 | $115K | |
| 97139 | <1% | 10,133 | $115K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 19,228 | $115K |
| 97165 | <1% | 2,765 | $114K | |
| 72146 | <1% | 232 | $113K | |
| 74455 | <1% | 1,012 | $113K | |
| 85651 | <1% | 18,049 | $109K | |
| 94375 | <1% | 1,590 | $109K | |
| 76870 | <1% | 3,066 | $108K | |
| 95816 | <1% | 1,136 | $107K | |
| 85007 | <1% | 16,092 | $106K | |
| 85610 | <1% | 6,448 | $105K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 10,374 | $104K |
| 85730 | <1% | 5,413 | $104K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 9,935 | $100K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 1,546 | $99K |
| 80069 | <1% | 8,524 | $94K | |
| 72170 | <1% | 4,309 | $94K | |
| 76827 | <1% | 1,263 | $94K | |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | <1% | 203 | $92K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,716 | $92K |
| 73140 | <1% | 5,911 | $91K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,835 | $90K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 8,829 | $89K |
| 97803 | <1% | 3,783 | $88K | |
| 73000 | <1% | 3,326 | $87K | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 2,522 | $85K |
| 93320 | <1% | 1,613 | $82K | |
| Z4310 | <1% | 6,193 | $81K | |
| 99368 | <1% | 3,841 | $81K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 46,359 | $81K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 30,974 | $81K |
| 92555 | <1% | 3,420 | $80K | |
| 82784 | <1% | 7,632 | $80K | |
| 82570 | <1% | 8,827 | $78K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 3,928 | $78K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,208 | $77K |
| 87505 | <1% | 2,226 | $73K | |
| 96450 | <1% | 278 | $72K | |
| 93229 | <1% | 264 | $72K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,896 | $70K |
| 70360 | <1% | 4,049 | $69K | |
| 74019 | <1% | 4,676 | $69K | |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | <1% | 26,515 | $68K |
| 73130 | <1% | 4,104 | $67K | |
| 87081 | <1% | 12,254 | $67K | |
| 73560 | <1% | 2,731 | $66K | |
| 86160 | <1% | 2,957 | $66K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 9,780 | $66K |
| 0636 | <1% | 2,635 | $65K | |
| 85045 | <1% | 6,541 | $65K | |
| 87186 | <1% | 6,869 | $65K | |
| J2704 | Injection, propofol, 10 mg | <1% | 16,920 | $65K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 24,110 | $63K |
| 85240 | <1% | 2,845 | $63K | |
| 83970 | <1% | 1,342 | $62K | |
| 92522 | <1% | 949 | $61K | |
| 76825 | <1% | 1,215 | $61K | |
| 85397 | <1% | 2,493 | $61K | |
| 88304 | <1% | 6,157 | $60K | |
| 0270 | <1% | 48,255 | $58K | |
| 96409 | <1% | 2,250 | $57K | |
| 85246 | <1% | 2,534 | $57K | |
| 73564 | <1% | 1,789 | $57K | |
| 94664 | <1% | 3,885 | $56K | |
| 87040 | <1% | 4,753 | $55K | |
| 73110 | <1% | 3,083 | $53K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 3,573 | $52K |
| V5010 | Assessment for hearing aid | <1% | 574 | $52K |
| 84156 | <1% | 7,529 | $51K | |
| 70220 | <1% | 1,495 | $51K | |
| 87077 | <1% | 7,411 | $51K | |
| 84466 | <1% | 3,761 | $50K | |
| 83540 | <1% | 3,859 | $49K | |
| V5008 | Hearing screening | <1% | 759 | $49K |
| J9370 | Vincristine sulfate, 1 mg | <1% | 3,573 | $48K |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 2,499 | $46K |
| X4544 | <1% | 356 | $43K | |
| 82785 | <1% | 1,926 | $43K | |
| 74230 | <1% | 383 | $43K | |
| 74240 | <1% | 397 | $43K | |
| 87070 | <1% | 3,214 | $42K | |
| 83690 | <1% | 12,539 | $42K | |
| 73562 | <1% | 2,252 | $41K | |
| 73080 | <1% | 2,182 | $40K | |
| 87631 | <1% | 1,831 | $40K | |
| 92521 | <1% | 1,967 | $40K | |
| 86480 | <1% | 1,380 | $39K | |
| 80061 | Lipid panel | <1% | 5,720 | $39K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 7,599 | $38K |
| 87581 | <1% | 2,455 | $37K | |
| G0378 | Hospital observation service, per hour | <1% | 1,313 | $37K |
| 76801 | <1% | 1,137 | $37K | |
| 87486 | <1% | 2,395 | $36K | |
| 96111 | <1% | 340 | $36K | |
| 76813 | <1% | 1,659 | $36K | |
| 93308 | <1% | 731 | $35K | |
| 73060 | <1% | 1,293 | $34K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 7,778 | $34K |
| 97010 | <1% | 5,193 | $34K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,665 | $34K |
| 97161 | <1% | 986 | $34K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,533 | $33K |
| 82803 | <1% | 3,367 | $33K | |
| 70486 | <1% | 275 | $33K | |
| 92611 | <1% | 275 | $32K | |
| 83735 | <1% | 5,115 | $31K | |
| 92570 | <1% | 2,182 | $31K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 15,418 | $29K |
| 84145 | <1% | 3,162 | $29K | |
| 73552 | <1% | 1,619 | $29K | |
| 95012 | <1% | 1,302 | $29K | |
| 83516 | <1% | 6,912 | $29K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,005 | $28K |
| 87430 | <1% | 5,577 | $28K | |
| 83605 | <1% | 3,206 | $27K | |
| 84305 | <1% | 1,285 | $27K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,326 | $27K |
| 91065 | <1% | 1,194 | $27K | |
| Q9958 | High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml | <1% | 1,265 | $26K |
| 86171 | <1% | 1,976 | $26K | |
| 73030 | <1% | 1,427 | $26K | |
| 94760 | <1% | 11,649 | $25K | |
| 80197 | <1% | 1,414 | $25K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,297 | $24K |
| 85384 | <1% | 731 | $24K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,450 | $24K |
| 73620 | <1% | 1,153 | $23K | |
| X4540 | <1% | 714 | $23K | |
| 87799 | <1% | 418 | $23K | |
| X4110 | <1% | 766 | $23K | |
| 82330 | <1% | 3,471 | $23K | |
| 86635 | <1% | 2,212 | $23K | |
| 76885 | <1% | 283 | $22K | |
| 94644 | <1% | 1,670 | $22K | |
| 86850 | <1% | 1,800 | $21K | |
| Z7504 | <1% | 422 | $21K | |
| 83615 | <1% | 3,138 | $21K | |
| 54640 | <1% | 74 | $21K | |
| 84703 | <1% | 9,850 | $21K | |
| 73600 | <1% | 646 | $20K | |
| 93226 | <1% | 477 | $20K | |
| 92579 | <1% | 519 | $19K | |
| 97804 | <1% | 759 | $19K | |
| 76820 | <1% | 1,296 | $19K | |
| 87497 | <1% | 316 | $19K | |
| 70491 | <1% | 83 | $19K | |
| 86235 | <1% | 993 | $19K | |
| 86923 | <1% | 509 | $18K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,072 | $18K |
| 82977 | <1% | 3,130 | $18K | |
| Z7512 | <1% | 673 | $17K | |
| 77072 | <1% | 1,135 | $17K | |
| 70543 | <1% | 14 | $17K | |
| 72100 | <1% | 1,166 | $17K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 443 | $17K |
| Z4303 | <1% | 387 | $17K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,502 | $16K |
| 99243 | <1% | 182 | $16K | |
| 76010 | <1% | 1,101 | $15K | |
| 0324 | <1% | 187 | $15K | |
| 82610 | <1% | 1,090 | $15K | |
| 84550 | <1% | 2,491 | $15K | |
| 85027 | <1% | 2,200 | $15K | |
| 94621 | <1% | 102 | $14K | |
| X3920 | <1% | 278 | $14K | |
| 82947 | <1% | 4,938 | $14K | |
| 86901 | <1% | 2,689 | $14K | |
| 93225 | <1% | 481 | $14K | |
| 96367 | <1% | 291 | $13K | |
| 86900 | <1% | 2,602 | $13K | |
| 76821 | <1% | 355 | $13K | |
| X4304 | <1% | 400 | $13K | |
| 84100 | <1% | 3,040 | $12K | |
| 92556 | <1% | 156 | $12K | |
| 14040 | <1% | 29 | $12K | |
| 80076 | <1% | 1,439 | $12K | |
| X4500 | <1% | 123 | $12K | |
| 85390 | <1% | 1,107 | $11K | |
| Z7510 | <1% | 111 | $11K | |
| 82550 | <1% | 2,401 | $11K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 435 | $11K |
| 86038 | <1% | 2,292 | $11K | |
| Z7508 | <1% | 184 | $11K | |
| Q9960 | High osmolar contrast material, 200-249 mg/ml iodine concentration, per ml | <1% | 550 | $11K |
| 84484 | <1% | 1,390 | $11K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 2,286 | $11K |
| 87507 | <1% | 178 | $11K | |
| 29075 | <1% | 1,629 | $11K | |
| X4112 | <1% | 577 | $11K | |
| 86003 | <1% | 2,732 | $10K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,324 | $10K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,228 | $10K |
| 80074 | <1% | 571 | $10K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,917 | $10K |
| 96379 | <1% | 3,031 | $9K | |
| 99199 | Unlisted special service, procedure or report | <1% | 153 | $9K |
| 86359 | <1% | 567 | $9K | |
| 86357 | <1% | 558 | $9K | |
| 86355 | <1% | 557 | $9K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 363 | $9K |
| 86360 | <1% | 557 | $9K | |
| 72040 | <1% | 621 | $9K | |
| 77073 | <1% | 200 | $9K | |
| 72197 | <1% | 18 | $8K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 33 | $8K |
| 76882 | <1% | 327 | $8K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 1,531 | $8K |
| 77075 | <1% | 109 | $8K | |
| 70250 | <1% | 320 | $8K | |
| 88184 | <1% | 184 | $8K | |
| 86225 | <1% | 1,656 | $8K | |
| 87046 | <1% | 875 | $8K | |
| 73723 | <1% | 12 | $8K | |
| 84403 | <1% | 583 | $8K | |
| 71020 | <1% | 572 | $7K | |
| 86255 | <1% | 1,788 | $7K | |
| 84132 | <1% | 3,256 | $7K | |
| J9260 | Injection, methotrexate sodium, 50 mg | <1% | 915 | $7K |
| 84295 | <1% | 3,177 | $7K | |
| X4530 | <1% | 149 | $7K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,979 | $7K |
| 83520 | <1% | 889 | $7K | |
| 83021 | <1% | 491 | $7K | |
| 82340 | <1% | 521 | $6K | |
| 70260 | <1% | 117 | $6K | |
| 84702 | <1% | 755 | $6K | |
| 96132 | <1% | 54 | $6K | |
| 99366 | <1% | 193 | $6K | |
| 87660 | <1% | 866 | $5K | |
| 54300 | <1% | 14 | $5K | |
| 93786 | <1% | 413 | $5K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 227 | $5K |
| Z4309 | <1% | 215 | $5K | |
| 80180 | <1% | 1,016 | $5K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,792 | $5K |
| 86200 | <1% | 500 | $5K | |
| V5264 | Ear mold/insert, not disposable, any type | <1% | 93 | $5K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 998 | $5K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 995 | $5K |
| 86331 | <1% | 499 | $5K | |
| 84436 | <1% | 622 | $5K | |
| 83993 | <1% | 927 | $5K | |
| 84480 | <1% | 177 | $4K | |
| 86308 | <1% | 1,364 | $4K | |
| 82657 | <1% | 426 | $4K | |
| 54161 | <1% | 13 | $4K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 53 | $4K |
| 86481 | <1% | 116 | $4K | |
| 87420 | <1% | 394 | $4K | |
| 89051 | <1% | 550 | $4K | |
| 88187 | <1% | 114 | $4K | |
| 82043 | <1% | 641 | $4K | |
| X4301 | <1% | 43 | $4K | |
| 85014 | <1% | 3,226 | $4K | |
| 86376 | <1% | 906 | $4K | |
| A4217 | Sterile water/saline, 500 ml | <1% | 3,898 | $4K |
| 82105 | <1% | 295 | $4K | |
| 82150 | <1% | 595 | $4K | |
| 90686 | <1% | 234 | $4K | |
| 86039 | <1% | 395 | $4K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 824 | $4K |
| 87205 | <1% | 930 | $3K | |
| 76886 | <1% | 53 | $3K | |
| 85247 | <1% | 94 | $3K | |
| 0320 | <1% | 49 | $3K | |
| 0369 | <1% | 26 | $3K | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 7,237 | $3K |
| 96113 | <1% | 45 | $3K | |
| 88108 | <1% | 205 | $3K | |
| 86147 | <1% | 194 | $3K | |
| 86800 | <1% | 548 | $3K | |
| 76881 | <1% | 27 | $3K | |
| 86146 | <1% | 181 | $3K | |
| 93270 | <1% | 65 | $3K | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 1,486 | $3K |
| 0271 | <1% | 288 | $3K | |
| 73660 | <1% | 527 | $3K | |
| 94729 | <1% | 24 | $3K | |
| 92550 | <1% | 76 | $3K | |
| 96415 | <1% | 61 | $3K | |
| 99070 | <1% | 3,001 | $3K | |
| 83880 | <1% | 216 | $3K | |
| 82533 | <1% | 97 | $3K | |
| 88185 | <1% | 118 | $3K | |
| 86431 | <1% | 742 | $3K | |
| 88104 | <1% | 339 | $2K | |
| Z9725 | <1% | 56 | $2K | |
| 59025 | Fetal non-stress test | <1% | 324 | $2K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,446 | $2K |
| 72070 | <1% | 195 | $2K | |
| 76000 | <1% | 41 | $2K | |
| 82103 | <1% | 460 | $2K | |
| 74183 | <1% | 13 | $2K | |
| X4535 | <1% | 43 | $2K | |
| 44970 | <1% | 12 | $2K | |
| 0300 | <1% | 18 | $2K | |
| X3908 | <1% | 63 | $2K | |
| 82272 | <1% | 323 | $2K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 156 | $2K |
| 94645 | <1% | 400 | $2K | |
| 95812 | <1% | 13 | $2K | |
| 86777 | <1% | 99 | $2K | |
| 80195 | <1% | 124 | $2K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,382 | $2K |
| 84520 | <1% | 192 | $2K | |
| 82248 | <1% | 1,279 | $1K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 840 | $1K |
| V5267 | Hearing aid or assistive listening device/supplies/accessories, not otherwise specified | <1% | 12 | $1K |
| 82247 | <1% | 1,168 | $1K | |
| 82945 | <1% | 329 | $1K | |
| 82810 | <1% | 28 | $1K | |
| 76800 | <1% | 53 | $1K | |
| 85245 | <1% | 67 | $1K | |
| 84157 | <1% | 329 | $1K | |
| 76506 | <1% | 30 | $1K | |
| 76499 | <1% | 26 | $1K | |
| 74000 | <1% | 144 | $1K | |
| 81374 | <1% | 100 | $981.03 | |
| 42821 | <1% | 14 | $934.39 | |
| 86317 | <1% | 103 | $928.03 | |
| 96136 | <1% | 24 | $921.36 | |
| 96411 | <1% | 33 | $903.24 | |
| Z4302 | <1% | 71 | $873.63 | |
| Z5406 | <1% | 55 | $843.50 | |
| 94770 | <1% | 43 | $826.46 | |
| 86592 | <1% | 325 | $810.02 | |
| 84446 | <1% | 81 | $789.75 | |
| 73120 | <1% | 58 | $769.14 | |
| 83002 | <1% | 476 | $712.52 | |
| 77080 | <1% | 26 | $698.21 | |
| 86664 | <1% | 512 | $688.95 | |
| 82565 | <1% | 161 | $667.85 | |
| 84590 | <1% | 56 | $658.00 | |
| X3910 | <1% | 35 | $649.44 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 631 | $647.50 |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 12 | $643.90 |
| 83001 | <1% | 382 | $627.20 | |
| 83655 | <1% | 704 | $613.90 | |
| 86902 | <1% | 52 | $606.03 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 4,577 | $595.28 |
| 85379 | <1% | 103 | $574.75 | |
| 96040 | <1% | 31 | $571.20 | |
| 85290 | <1% | 25 | $559.99 | |
| Z5910 | <1% | 12 | $559.44 | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 12 | $548.88 |
| 86665 | <1% | 495 | $545.29 | |
| 74020 | <1% | 48 | $526.92 | |
| 84402 | <1% | 57 | $435.00 | |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 182 | $434.92 |
| 98960 | <1% | 26 | $428.05 | |
| 82670 | <1% | 205 | $425.02 | |
| 85230 | <1% | 13 | $424.86 | |
| 87101 | <1% | 36 | $404.26 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 245 | $394.53 |
| 82104 | <1% | 137 | $386.00 | |
| 82270 | <1% | 179 | $381.10 | |
| 93271 | <1% | 13 | $368.34 | |
| 83498 | <1% | 58 | $360.40 | |
| 96127 | <1% | 24 | $350.37 | |
| 71010 | <1% | 43 | $349.07 | |
| 87184 | <1% | 27 | $342.30 | |
| 74220 | <1% | 13 | $305.43 | |
| 82390 | <1% | 302 | $292.50 | |
| 82435 | <1% | 117 | $273.73 | |
| 84460 | <1% | 43 | $209.95 | |
| 84450 | <1% | 41 | $206.21 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 109 | $191.56 |
| 87338 | <1% | 413 | $184.46 | |
| 84681 | <1% | 61 | $183.00 | |
| 87206 | <1% | 23 | $182.64 | |
| 91200 | <1% | 14 | $179.36 | |
| 96376 | <1% | 128 | $162.91 | |
| 84244 | <1% | 38 | $162.25 | |
| 82652 | <1% | 13 | $128.00 | |
| 87340 | <1% | 81 | $120.96 | |
| 82157 | <1% | 16 | $115.28 | |
| 83525 | <1% | 13 | $108.61 | |
| 84146 | <1% | 28 | $104.80 | |
| Q4051 | Splint supplies, miscellaneous (includes thermoplastics, strapping, fasteners, padding and other supplies) | <1% | 501 | $104.62 |
| 87177 | <1% | 132 | $103.73 | |
| 83625 | <1% | 173 | $102.34 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 39 | $101.64 |
| 84478 | <1% | 42 | $84.26 | |
| 72110 | <1% | 13 | $74.87 | |
| 87328 | <1% | 36 | $65.72 | |
| 82040 | <1% | 14 | $60.71 | |
| 86803 | <1% | 24 | $49.60 | |
| 93788 | <1% | 16 | $48.99 | |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 18 | $46.89 |
| 86663 | <1% | 42 | $45.69 | |
| 82627 | <1% | 29 | $43.20 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 4,066 | $32.22 |
| T5999 | Supply, not otherwise specified | <1% | 38 | $30.38 |
| 82607 | <1% | 24 | $22.80 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 12 | $13.94 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 245 | $9.14 |
| 70160 | 0% | 33 | $0.00 | |
| 29065 | 0% | 668 | $0.00 | |
| 29405 | 0% | 60 | $0.00 | |
| 94762 | 0% | 70 | $0.00 | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMYCROFT, TINA (SVP & CFO)
| Provider | Location | Paid |
|---|---|---|
| Valley Children's Hospital | Madera, CA | $22.84M |
| Valley Children's Hospital | Fresno, CA | $20.85M |
| Valley Children's Hospital | Madera, CA | $14.28M |
| ST Jude Hospital Yorba Linda | Santa Rosa, CA | $10.59M |
| Valley Children's Hospital | Madera, CA | $262K |
| Valley Children's Hospital | Fresno, CA | $53K |
| King County Public Hospital District No. 2 | Kirkland, WA | $10K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.